Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 DiabetesManuela Battaglia, Mark Peakman, Linda A. DiMeglio et al.|Diabetes Care|2019Cited by 350
Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 DiabetesMichael J. Haller, W. J. Russell, Desmond Schatz et al.|Diabetes Care|2018Cited by 183
Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial DataMichael J. Haller, Louis H. Philipson, S. Alice Long et al.|Diabetes|2019Cited by 132
The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screeningLaura M. Jacobsen, Jay M. Sosenko, Laura E. Bocchino et al.|Diabetologia|2019Cited by 130